BUL719 (alpelisib) was used in the treatment of PIK3CA-mutated advanced/recurrent cervical cancer where at least two lines of therapy have failed, in a small study from Istituto Nazionale dei Tumori (Milano, Italy). The gene discussed is PIK3CA; the disease is cervical carcinoma.